Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair

Who can take part

• Ages 18-80
• Participants with unruptured cerebral aneurysms eligible for stent-assisted coiling or flow diversion devices
• Completion of preoperative antiplatelet preparation
• Signed informed consent

Who cannot take part

• Antiplatelet drug (exclude aspirin and clopidogrel) being taken within 72 hours; anticoagulant drug (including heparin or oral anticoagulants) being taken within 10 days
• Participants with recurrent aneurysms who have received neurointerventional treatment
• Allergy to study drugs and anesthetics
• Known history of intracranial tumor, arteriovenous malformation, arteriovenous fistula, venous sinus thrombosis, hereditary cerebral small vessel disease, peripheral hemangioma (e.g., aortic aneurysm, limb vascular aneurysm)
• Known history of cerebral parenchymal hemorrhage, subarachnoid hemorrhage, cerebral infarction, transient ischemic attack, or gastrointestinal bleeding within 6 months
• Clear indications for anticoagulation (presumed cardiac source of embolus, e.g., atrial fibrillation, prosthetic cardiac valves known or suspected endocarditis)
• Severe heart failure (NYHA classes III and IV) or severe arrhythmias, including sick sinus syndrome, severe atrioventricular block, and bradycardia-related syncope
• Abnormal platelet count (normal reference is 100-300×10\^9/L)
• Severe renal (creatinine exceeding 1.5 times of the upper limit of normal range) or hepatic (ALT or AST > twice the upper limit of normal range) insufficiency
• Contradictory to MRI examination
• Inability to follow endovascular procedures due to anatomical difficulties
• Pregnant